PHA/PVRI Joint Session: The Real-World Evidence in PAH
 

Description: 
Traditional randomized clinical trials are  powerful tools for developing scientific evidence about therapeutic interventions. RCTs guide regulato,ry approval of new drugs and devices, and are the foundation of clinical guidelines. Yet, RCTs recruit highly selected populations and manage them in controlled settings, which makes it difficult to generalize the results to broader, diverse populations seen  in clinical practice. Clinicians, regulators, payers and the pharaceutical industry increasingly recognize the use of real‐world evidence to complement to knowledge gained from RCTs. During this session, the presenters will discuss the meaning of RWE in the context of pulmonary arterial hypertension, as well as  regulatory requirements for therapy approval based on  real-world evidence.

Featured Presenters:

Changing the Paradigm in Treating Patients with Pulmonary Hypertension and Parenchymal Lung Disease
 

Description: Pulmonary hypertension, which often occurs alongside parenchymal lung disease, significantly worsens the prognosis compared to having either condition alone. In this session, speakers will explore interstitial lung disease, chronic obstructive pulmonary disease and pediatric lung disease-associated pulmonary hypertension. The session will include a discussion of prior studies of pulmonary vasodilators; methods to identify patients with ILD and COPD who may respond to systemic pulmonary vasodilators; the success of the INCREASE trial and how to optimize the use of inhaled treprostinil. The session also will address future directions in studying this complex condition and unique challenges associated with  pediatric patients.

Featured Presenters: